TY - JOUR
T1 - Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea
AU - Dasari, Arvind
AU - Joish, Vijay N.
AU - Perez-Olle, Raul
AU - Dharba, Sam
AU - Balaji, Kavitha
AU - Halperin, Daniel M.
N1 - Funding Information:
This research was sponsored by Lexicon Pharmaceuticals, Inc. All authors participated in the design, conduct, analysis and interpretation of findings. Drs. Dasari and Halperin were reimbursed for their consulting hours funded by the sponsor. Medical writing support was provided by Jeff Frimpter, MPH, funded by Lexicon Pharmaceuticals, Inc.
Publisher Copyright:
© 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/9/2
Y1 - 2020/9/2
N2 - Objectives: We estimated the indirect costs of work productivity burden from carcinoid syndrome diarrhea (CSD) among employed, insured adults in the United States. Methods: Retrospective cohort study of patients ≥18 years old with CS who did and did not have CSD (2014–2016). Eligible patients had continuous health plan enrollment for ≥12 months prior to their first CS claim and for ≥30 days after. Univariate analyses of clinical and work productivity outcomes and indirect costs were conducted. Multivariate analyses examined associations of CSD with work productivity measures, controlling for baseline characteristics. Results: A total of 1,880 patients with CS were eligible, including 577 with CSD and 1,303 with CS only. Baseline characteristics were generally similar. Patients with CSD missed half of eligible workdays (median 56%, 146/260); those with CS-only missed one-third (38%, 100/260). Work productivity was lower and the associated costs were higher in the presence of CSD. Patients with CSD had more absenteeism, short-term disability, and lost workdays which translated into incremental mean costs of $16,679 greater than those with CS only. Conclusion: Indirect costs related to work productivity losses among adults with CSD are significant, which further add to the burden of CSD to society.
AB - Objectives: We estimated the indirect costs of work productivity burden from carcinoid syndrome diarrhea (CSD) among employed, insured adults in the United States. Methods: Retrospective cohort study of patients ≥18 years old with CS who did and did not have CSD (2014–2016). Eligible patients had continuous health plan enrollment for ≥12 months prior to their first CS claim and for ≥30 days after. Univariate analyses of clinical and work productivity outcomes and indirect costs were conducted. Multivariate analyses examined associations of CSD with work productivity measures, controlling for baseline characteristics. Results: A total of 1,880 patients with CS were eligible, including 577 with CSD and 1,303 with CS only. Baseline characteristics were generally similar. Patients with CSD missed half of eligible workdays (median 56%, 146/260); those with CS-only missed one-third (38%, 100/260). Work productivity was lower and the associated costs were higher in the presence of CSD. Patients with CSD had more absenteeism, short-term disability, and lost workdays which translated into incremental mean costs of $16,679 greater than those with CS only. Conclusion: Indirect costs related to work productivity losses among adults with CSD are significant, which further add to the burden of CSD to society.
KW - Carcinoid syndrome
KW - carcinoid syndrome diarrhea
KW - indirect costs
KW - neuroendocrine tumors
KW - work productivity
UR - http://www.scopus.com/inward/record.url?scp=85071190882&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071190882&partnerID=8YFLogxK
U2 - 10.1080/14737167.2019.1660646
DO - 10.1080/14737167.2019.1660646
M3 - Article
C2 - 31448649
AN - SCOPUS:85071190882
SN - 1473-7167
VL - 20
SP - 507
EP - 511
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
IS - 5
ER -